Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Prior treatment

• Patients who have a condition requiring systemic treatment with either prednisone or other immunosuppressive medications;
• Patients who have received prior chemotherapy, anti-angiogenesis therapy and immunotherapy for this malignancy or for any other past malignancy;
• Patients who have received prior treatment for non-small cell lung cancer;

Other illness

• Patients with active autoimmune disease or history of autoimmune disease;
• Patients with a history of symptomatic interstitial lung disease;
• History of allergy to study drug components;
• Any mental or psychological condition which would not permit the patient to complete the study or understand the patient information;
• Patients with high risk of major bleeding;
• Patients who have prior malignancies;
• HIV, HBV, HCV infection or active pulmonary tuberculosis;
• Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.

Other

• Pancoast tumor, squamous cell carcinoma, large-cell carcinoma and sarcomatoid carcinoma;
• Women must not be pregnant or breast-feeding;
• Men with female partners that are not willing to use contraception;
• Patients who have major hemoptysis within the past 4 weeks, tumor has invasion or is close to great vessels;
• Patients who have arterial thrombotic events, esophageal varices, peptic ulcers, wounds or bone fractures;

• Histologically or cytologically confirmed, previously untreated and surgically resectable non-small cell lung cancer (stage II-IIIA, patients with squamous cell carcinoma or EGFR mutation should not be included);
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
• Satisfactory preoperative laboratory testing and adequate pulmonary function for surgery;
• Patients approve and sign the informed consent.